BACKGROUND AND PURPOSE: The endogenous cannabinoid system participates in oligodendrocyte progenitor differentiation in vitro. To determine the effect of synthetic cannabinoids on oligodendrocyte differentiation, we exposed differentiating cultures of oligodendrocytes with cannabinoid CB(1), CB(2) and CB(1)/CB(2) receptor agonists and antagonists. The response of the PI3K/Akt and the mammalian target of rapamycin (mTOR) signalling pathways were studied as effectors of cannabinoid activity. EXPERIMENTAL APPROACH: Purified oligodendrocyte progenitor cells (OPC) obtained from primary mixed glial cell cultures were treated for 48 h with CB(1), CB(2) and CB(1) /CB(2) receptor agonists (ACEA, JWH133 and HU210, respectively) in the presence or absence of the antagonists AM281 (CB(1) receptor) and AM630 (CB(2) receptor). Moreover, inhibitors of the phosphatidylinositol 3-kinase (PI3K)/Akt and mTOR pathways (LY294002 and rapamycin, respectively) were used to study the involvement of these pathways on cannabinoid-induced OPC maturation. KEY RESULTS: ACEA, JWH133 and HU-210 enhanced OPC differentiation as assessed by the expression of stage specific antigens and myelin basic protein (MBP). Moreover, this effect was blocked by the CB receptor antagonists. ACEA, JWH133 and HU210 induced a time-dependent phosphorylation of Akt and mTOR, whereas the inhibitors of PI3K/Akt (LY294002) or of mTOR (rapamycin) reversed the effects of HU-210 on oligodendrocyte differentiation and kinase activation. CONCLUSIONS AND IMPLICATIONS: Activation of cannabinoid CB(1) or CB(2) receptors with selective agonists accelerated oligodendrocyte differentiation through the mTOR and Akt signalling pathways.
BACKGROUND AND PURPOSE: The endogenous cannabinoid system participates in oligodendrocyte progenitor differentiation in vitro. To determine the effect of synthetic cannabinoids on oligodendrocyte differentiation, we exposed differentiating cultures of oligodendrocytes with cannabinoidCB(1), CB(2) and CB(1)/CB(2) receptor agonists and antagonists. The response of the PI3K/Akt and the mammalian target of rapamycin (mTOR) signalling pathways were studied as effectors of cannabinoid activity. EXPERIMENTAL APPROACH: Purified oligodendrocyte progenitor cells (OPC) obtained from primary mixed glial cell cultures were treated for 48 h with CB(1), CB(2) and CB(1) /CB(2) receptor agonists (ACEA, JWH133 and HU210, respectively) in the presence or absence of the antagonists AM281 (CB(1) receptor) and AM630 (CB(2) receptor). Moreover, inhibitors of the phosphatidylinositol 3-kinase (PI3K)/Akt and mTOR pathways (LY294002 and rapamycin, respectively) were used to study the involvement of these pathways on cannabinoid-induced OPC maturation. KEY RESULTS:ACEA, JWH133 and HU-210 enhanced OPC differentiation as assessed by the expression of stage specific antigens and myelin basic protein (MBP). Moreover, this effect was blocked by the CB receptor antagonists. ACEA, JWH133 and HU210 induced a time-dependent phosphorylation of Akt and mTOR, whereas the inhibitors of PI3K/Akt (LY294002) or of mTOR (rapamycin) reversed the effects of HU-210 on oligodendrocyte differentiation and kinase activation. CONCLUSIONS AND IMPLICATIONS: Activation of cannabinoidCB(1) or CB(2) receptors with selective agonists accelerated oligodendrocyte differentiation through the mTOR and Akt signalling pathways.
Authors: J Romero; E Garcia-Palomero; F Berrendero; L Garcia-Gil; M L Hernandez; J A Ramos; J J Fernández-Ruiz Journal: Synapse Date: 1997-07 Impact factor: 2.562
Authors: M Bouaboula; C Poinot-Chazel; B Bourrié; X Canat; B Calandra; M Rinaldi-Carmona; G Le Fur; P Casellas Journal: Biochem J Date: 1995-12-01 Impact factor: 3.857
Authors: W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam Journal: Science Date: 1992-12-18 Impact factor: 47.728
Authors: T Sugiura; S Kondo; A Sukagawa; S Nakane; A Shinoda; K Itoh; A Yamashita; K Waku Journal: Biochem Biophys Res Commun Date: 1995-10-04 Impact factor: 3.575
Authors: R Mechoulam; S Ben-Shabat; L Hanus; M Ligumsky; N E Kaminski; A R Schatz; A Gopher; S Almog; B R Martin; D R Compton Journal: Biochem Pharmacol Date: 1995-06-29 Impact factor: 5.858
Authors: F Berrendero; L García-Gil; M L Hernández; J Romero; M Cebeira; R de Miguel; J A Ramos; J J Fernández-Ruiz Journal: Development Date: 1998-08 Impact factor: 6.868
Authors: Oscar Gomez; Maria A Sanchez-Rodriguez; Silvia Ortega-Gutierrez; Henar Vazquez-Villa; Carmen Guaza; Francisco Molina-Holgado; Eduardo Molina-Holgado Journal: J Neuroimmune Pharmacol Date: 2015-04-22 Impact factor: 4.147
Authors: Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza Journal: J Neurosci Date: 2017-07-27 Impact factor: 6.167
Authors: Joseph E Henriquez; Michael D Rizzo; Matthias A Schulz; Robert B Crawford; Peter Gulick; Norbert E Kaminski Journal: J Acquir Immune Defic Syndr Date: 2017-08-15 Impact factor: 3.731
Authors: Yan Yang; Haibo Wang; Jie Zhang; Fucheng Luo; Karl Herrup; James A Bibb; Richard Lu; Robert H Miller Journal: Dev Biol Date: 2013-04-10 Impact factor: 3.582